BMO Capital Markets said Biogen Inc BIIB shares should trade higher, despite a recent drug trial miss, on CTAD data (Clinical Trials on Alzheimer's Disease).
The CTAD data show:
However, the brokerage maintains its Market Perform rating on Biogen shares, with a price target of $331.
To Go More Bullish
“In order to get more constructive on BIIB, on Friday, we want to see data regarding: (1) ARIA-E severity in titration cohort; (2) 24- month efficacy magnitude; and (3) cognitive benefit from placebo patients switching to aducanumab in LTE,” analyst Ian Somaiya wrote in a note.
Earlier in Friday's morning session, hares of Biogen rose 5.13 percent to $304.39; however, at last check, shares were up just 0.94 percent at $292.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.